Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

BOLD-100 shows robust preclinical efficacy against COVID-19 variants

April 19, 2021

Carrimycin studied in phase III to treat severe COVID-19 in hospitalized patients

April 19, 2021

Icatibant portion of I-SPY COVID trial ends after futility criterion met

April 16, 2021

Merck & Co. discontinues development of MK-7110 for COVID-19

April 16, 2021

INO-4800 provides broad cross-reactive immune responses against variant strains of SARS-CoV-2

April 16, 2021

First volunteer dosed in phase I study of COVID-19 candidate HLX-71

April 16, 2021

Phase III study of ciclesonide inhaler in COVID-19 does not meet statistical significance

April 16, 2021

GLS-1027 studied in phase II to prevent severe pneumonitis caused by SARS-CoV-2

April 16, 2021

New promising Johnson & Johnson cyclic HBV capsid assembly modulator series

April 15, 2021

Shanghai Sun-Sail Pharmaceutical Science & Technology patents antituberculosis compounds

April 15, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...